| Home | Log In | Register | Our Services | My Account | Contact | Help |
- 20 Feb 2004 09:34


- 30 May 2005 14:46
- 5092 of 27111
- 30 May 2005 15:29
- 5093 of 27111
- 30 May 2005 15:37
- 5094 of 27111
- 30 May 2005 15:59
- 5095 of 27111
- 30 May 2005 16:17
- 5096 of 27111
Hi All,
Some posters claim to be experts, but what do the REAL qualified experts say ????
Tim Freeborne - Stanelco Analyst for Evolution Beeson Gregory
Tim covers a range of industrial and technology companies, with emphasis on high growth situations. After reading philosophy at university he qualified as a chartered accountant and specialised in corporate tax. For 12 years he was a City reporter with the Daily Mail and then worked briefly in venture capital. He later edited a tipsheet and wrote part-time for Shares Magazine. Tim joined Evolution in October 2004.
All the following quotes are taken from Evolution Beeson Gregory Brokers Notes, 'EVO' are FSA regulated, is anyone here FSA regulated, or a member of the Securities Institute or other professional investment body/authorithy ????
Evolution Securities Ltd (Evolution Securities) (Incorporated in England No.2316630), which is authorised and regulated in the United Kingdom by the Financial Services Authority for designated investment business and is a member of the London Stock Exchange.
First, lets look at the Patent Dispute.
11 January 2005 - 'Initiating Coverage'
In a High Court hearing last year it was held that Stanelco had breached the terms of a non-disclosure agreement with BioProgress. The Court awarded BioProgress ownership of some patents issued by InGel but this ruling is being appealed. Without Stanelcos know-how and its other patents, it is very doubtful BioProgress can use these patents commercially. For this reason we believe it is unlikely that damages would be material
28 February
Litigation provisionThe figures include a 1.1m provision which we believe relates to the patent battle with BioProgress. Both sides are determined to prove they will defend their intellectual property rights. Stanelco is applying for leave to appeal against last years judgement, which left one patent with BioProgress.
24 March
The Bioprogress lawsuitOn 18 March the High Court gave Stanelco leave to appeal against last years ruling which granted a patent to Bioprogress. The judge ordered Bioprogress to pay Stanelco 9,750 towards its costs. He also froze the transfers of the patent. The encapsulation technology under dispute has no bearing on Greenseal. Its main importance is simply to show Stanelco will fight hard to defend its intellectual property.
Now a bit from KBC Hardman & CO
5 May 2005
The Legal ActionStanelco has been granted leave to appeal in the Bioprogress case. Effectively, the InGel joint venture and the detergent packaging business appear to bemothballed until further notice, since the ownership of the patents is still disputed. We have therefore adopted pretty much a scorched earth policy and removed any revenue from these areas from our forecasts. In the event that SEO wins the appeal we would expect to see a writeback of provisions made against legal costs.
Now lets look at the 'non-existent' competition issue.
11 January 2005 - 'Initiating Coverage'
The key issue for investors here is how difficult it will be for other RF companies to launch rival solutions. The field does not appear to be crowded. Most companies that offer RF sealing only do it as a minor sideline to heat-based solutions. Stanelco has over 50 years experience in the technology and we expect it will enjoy a lead of several years before rival solutions appear. The company has spent heavily on patent filings for various parts of the process and is confident several will be granted in the near future. It has seen no similar applications by other companies. The opportunity for RF may stretch far beyond the world of meat trays. Most areas of food packaging may benefit from the system. Wherever heat bonding is used, RF should be able to offer a cheaper alternative. Because of this astonishing potential we are not concerned in the short and even medium term about price erosion.
8 February
These numbers may seem far-fetched, but we believe they are likely to be cautious, certainly for the later years. The main risk from this point is the emergence of a rival system with similar cost-saving abilities. At the moment there seems to be nothing on the horizon and the company is investing heavily in legal protection of its intellectual property.
23 May
There is compelling evidence for believing Greenseal will win many orders. The key uncertainty is the durability of its patents. Stanelco has applied for broad patents covering the use of radio frequency in food sealing. Its agents report there are no previous filings which conflict in any way.
Also, the bashers were having a field day trying to scaremonger over the delay in the last 3 ASDA trials, but this bit tells the true story.
The downside of the Asda option is that three RF lidding trials with packagers are on hold because the lines in question are dedicated to rival supermarkets. The same packagers serve several supermarkets. Therefore Stanelco believes it will have a relatively easy task converting non-Asda lines after the end of the one yearexclusive.
Cheers,
PM
- 30 May 2005 16:18
- 5097 of 27111
- 30 May 2005 16:21
- 5098 of 27111
- 30 May 2005 17:12
- 5099 of 27111
- 30 May 2005 17:16
- 5100 of 27111
- 30 May 2005 17:25
- 5101 of 27111
- 30 May 2005 19:43
- 5102 of 27111
- 30 May 2005 19:49
- 5103 of 27111
- 30 May 2005 20:21
- 5104 of 27111
- 30 May 2005 21:33
- 5105 of 27111
- 30 May 2005 22:27
- 5106 of 27111
- 30 May 2005 22:32
- 5107 of 27111
- 30 May 2005 22:35
- 5108 of 27111
- 30 May 2005 23:03
- 5109 of 27111
- 30 May 2005 23:25
- 5110 of 27111
- 30 May 2005 23:50
- 5111 of 27111